Since 2010, Scott Robarge has served as the founding principal of Another8, where he recruits professionals for early and mid-stage tech companies in northern California. A native of Michigan and a graduate of the University of Michigan, Scott Robarge supports the Detroit Red Wings, which recently re-signed star center Dylan Larkin under a five-year contract.
A native of Waterford, Michigan, Dylan Larkin played for one season at the University of Michigan, where he earned the Big Ten Rookie of the Year award. The Red Wings drafted him as the 15th overall pick in the 2014 NHL Entry Draft, and he debuted with the team at the age of 19. During his rookie year, he earned a spot in the NHL All-Star Game and broke the record for the fastest skater competition.
Since then, Larkin has become one of the Red Wings’ leading players. In the 2017-18 season, he led the team in scoring and recorded 63 points in 82 games, which was almost double the number of points he made in the previous season. As a young player with significant experience for his age, Larkin will continue to be a key figure for the Red Wings over the next five years.
A business executive and recruiter, Scott Robarge is the principal and founder of Another8, a leading recruitment firm that connects skilled professionals with venture-backed startups and high-growth organizations. In a career spanning over 15 years, he has provided business and recruitment solutions to companies like Airbnb, Dropbox, LinkedIn, Facebook, Zendesk, Oracle, and many others. In this position, Scott Robarge takes advantage of digital recruitment tools such as Twitter to hire new talent.
Twitter, one of the most popular social media platforms worldwide, can be a powerful tool for finding skilled professionals through the site’s advanced search, Twitter list, and hashtag features.
Twitter’s advanced search option allows recruiters to search candidates through a single criterion or a combination of criteria including job title, industry, location, keywords, and hashtags. Twitter lists are also an efficient way to organize a feed and send out tweets exclusively to the intended accounts. Potential candidates can be quickly added to these lists so they will receive firsthand information for new job openings. Using hashtags is a simple way to search tweets for candidates who are actively looking for jobs.
University of Michigan
With more than 20 years of experience in the recruiting industry, Scott Robarge is the founder of Another8 in San Francisco. He typically recruits for Tier-1 venture capital companies looking for sales, product, engineering, and operations professionals. Additionally, Scott Robarge holds a bachelor’s in industrial and operations engineering from the University of Michigan (UM).
Recently, UM announced the appointment of a new dean of the School of Public Health, F. DuBois Bowman. Experienced with research in mental health disease and neurological disorders, including depression and Alzheimer’s disease, F. DuBois Bowman holds a master’s in biostatistics from UM and a PhD in biostatistics from the University of North Carolina at Chapel Hill. Effective October 15, he will start a five-year term not only as dean of the School of Public Health but also as a professor of biostatistics, with tenure.
Bowman comes to UM having served as chair of Columbia University’s Mailman School of Public Health and as the Cynthia and Robert Citrone-Roslyn and Leslie Goldstein Professor of Biostatistics. He stated that he is honored to join UM’s renowned School of Public Health, where students and faculty work to promote change through scientific evidence that informs future healthcare policy and community engagement.
A graduate of the University of Michigan with a bachelor’s in industrial and operations engineering, Scott Robarge has founded and headed recruiting companies including Alpine Recruiting and Another8. Outside of his current role at Another 8, Scott Robarge is a longtime supporter of the Alzheimer’s Association, which recently announced promising results of a new drug that may slow the progression of Alzheimer’s disease.
In a recent drug trial by biotech companies Eisai and Biogen, drug BAN2401 led to a 30 percent drop in mental decline for patients who received the highest dose of the drug. Ultimately, the drug didn’t meet the goals for the trial, but the experimental therapy removed a significant amount of sticky plaque accumulated in participants’ brains.
The results come with a few caveats, specifically related to the method used to measure mental decline. Researchers from the companies used a scale that blended sections of three commonly used tests, but they were the first to use such a measure. Also, the sample size was small, but results offer a bit of hope to families of patients with Alzheimer’s after several decades of failed clinical trials.